Differences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal Amphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic Aspergillus flavus Infections
- 1 January 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (1) , 218-230
Abstract
Given the recent increase in aspergillosis caused by species other than Aspergillus fumigatus , micafungin, caspofungin, and liposomal amphotericin B (L-AmBi) were investigated as monotherapy or combination therapy for murine systemic or pulmonary Aspergillus flavus infection. Treatment for 3 or 6 days was begun at 24 h (intravenous [i.v.], 2.8 × 10 4 conidia) or 2 h (intranasal, 4.1 × 10 6 to 6.75 × 10 6 conidia) postchallenge as follows: 5 or 10 mg/kg L-AmBi, 10 mg/kg caspofungin, 15 mg/kg micafungin, L-AmBi plus echinocandin, L-AmBi on days 1 to 3 and echinocandin on days 4 to 6, or echinocandin on days 1 to 3 and L-AmBi on days 4 to 6. Mice were monitored for survival, fungal burden, serum or tissue cytokines, and lung histopathology. In the systemic infection, micafungin or caspofungin was more effective than L-AmBi in prolonging survival ( P < 0.05), and L-AmBi was associated with significantly elevated serum levels of interleukin-6 (IL-6), macrophage inflammatory protein 1α (MIP-1α), and IL-12 ( P < 0.05). In contrast, L-AmBi was significantly more effective than the echinocandins in reducing fungal growth in most tissues ( P < 0.05). Concomitant therapies produced significantly enhanced survival, reduction in fungal burden, and low levels of proinflammatory cytokines, while antagonism was seen with some sequential regimens. In comparison, in the pulmonary infection, L-AmBi was significantly better ( P < 0.05) than caspofungin or the combination of L-AmBi and caspofungin in prolonging survival and reducing lung fungal burden. Caspofungin stimulated high lung levels of IL-1α, tumor necrosis factor alpha (TNF-α), and IL-6, with extensive tissue damage. In summary, systemic A flavus infection was treated effectively with L-AmBi plus micafungin or caspofungin provided that the drugs were administered concomitantly and not sequentially, while pulmonary A. flavus infection responded well to L-AmBi but not to caspofungin.Keywords
This publication has 47 references indexed in Scilit:
- In Vitro Echinocandin Susceptibility of Aspergillus Isolates from Patients Enrolled in the Transplant-Associated Infection Surveillance NetworkAntimicrobial Agents and Chemotherapy, 2011
- In Vitro Activity and In Vivo Efficacy of Anidulafungin in Murine Infections by Aspergillus flavusAntimicrobial Agents and Chemotherapy, 2011
- Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus InfectionsAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2010
- Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008
- Caspofungin Modulates Inflammatory Responses toAspergillus fumigatusthrough Stage‐Specific Effects on Fungal β‐Glucan ExposureThe Journal of Infectious Diseases, 2008
- Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B ProductsAntimicrobial Agents and Chemotherapy, 2008
- Efficacy of Caspofungin against Aspergillus flavus , Aspergillus terreus , and Aspergillus nidulansAntimicrobial Agents and Chemotherapy, 2006
- Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus InfectionAntimicrobial Agents and Chemotherapy, 2006
- The damage-response framework of microbial pathogenesisNature Reviews Microbiology, 2003